thalidomide has been researched along with Allergic Cutaneous Angiitis in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | 7.74 | Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 7.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties." | 5.33 | Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. ( Cem Ar, M; Hatemi, G; Salihoglu, A; Soysal, T; Ulku, B; Yazici, H, 2005) |
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | 3.74 | Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 3.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties." | 1.33 | Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. ( Cem Ar, M; Hatemi, G; Salihoglu, A; Soysal, T; Ulku, B; Yazici, H, 2005) |
| "All patients had oral and genital aphthae, and 22 of 25 patients had cutaneous lesions consistent with Behçet's disease." | 1.29 | Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. ( Jorizzo, JL; Mangelsdorf, HC; White, WL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, YH | 1 |
| Wei, KC | 1 |
| Yu, MS | 1 |
| Manni, E | 1 |
| Cervadoro, E | 1 |
| Papineschi, F | 1 |
| Loree, JM | 1 |
| Cai, E | 1 |
| Sheffield, BS | 1 |
| Dutz, JP | 1 |
| Villa, D | 1 |
| Shepherd, LE | 1 |
| Connors, JM | 1 |
| Sehn, LH | 1 |
| Savage, KJ | 1 |
| Salas-Espíndola, Y | 1 |
| Peniche-Castellanos, A | 1 |
| López-Gehrke, I | 1 |
| Mercadillo-Pérez, P | 1 |
| Alexander, MP | 1 |
| Nasr, SH | 1 |
| Watson, DC | 1 |
| Méndez, GP | 1 |
| Rennke, HG | 1 |
| Rechner, I | 1 |
| Brito-Babapulle, F | 1 |
| Fielden, J | 1 |
| Witzens, M | 1 |
| Moehler, T | 1 |
| Neben, K | 1 |
| Fruehauf, S | 1 |
| Hartschuh, W | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Cem Ar, M | 1 |
| Soysal, T | 1 |
| Hatemi, G | 1 |
| Salihoglu, A | 1 |
| Yazici, H | 1 |
| Ulku, B | 1 |
| Yildirim, ND | 1 |
| Ayer, M | 1 |
| Küçükkaya, RD | 1 |
| Alpay, N | 1 |
| Mete, O | 1 |
| Yenerel, MN | 1 |
| Yavuz, AS | 1 |
| Nalçaci, M | 1 |
| Mangelsdorf, HC | 1 |
| White, WL | 1 |
| Jorizzo, JL | 1 |
| Naafs, B | 1 |
| Faber, WR | 1 |
1 review available for thalidomide and Allergic Cutaneous Angiitis
| Article | Year |
|---|---|
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cuti | 2011 |
10 other studies available for thalidomide and Allergic Cutaneous Angiitis
| Article | Year |
|---|---|
Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
Topics: Antineoplastic Agents; Bortezomib; Dapsone; Dermatologic Agents; Dexamethasone; Humans; Male; Middle | 2021 |
Case of erythema elevatum diutinum associated with IgA paraproteinemia successfully controlled with thalidomide and plasma exchange.
Topics: Aged, 80 and over; Humans; Immunoglobulin A; Immunosuppressive Agents; Male; Paraproteinemias; Plasm | 2015 |
Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.
Topics: Antineoplastic Agents; Biopsy; Bone Marrow; Female; Humans; Immunophenotyping; Lenalidomide; Lymphom | 2017 |
[Leukocytoclastic vasculitis related to cocaine use].
Topics: Adrenal Cortex Hormones; Antibodies, Antineutrophil Cytoplasmic; Cocaine; Cocaine-Related Disorders; | 2011 |
Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Combined Modality Th | 2003 |
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aut | 2004 |
Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma.
Topics: Cryoglobulinemia; Dexamethasone; Disease Management; Drug Therapy, Combination; Female; Humans; Midd | 2005 |
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Hu | 2007 |
Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Behcet Syndrome; Colchic | 1996 |
Thalidomide therapy. An open trial.
Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu | 1985 |